

Review

Role of phospholipase C ϵ in physiological phosphoinositide signaling networksAlan V. Smrcka^{a,b,c,*}, Joan Heller Brown^d, George G. Holz^e^a Department of Pharmacology and Physiology, University of Rochester School of Medicine, 601 Elmwood Ave, Rochester, NY 14642, United States^b Department of Biochemistry and Biophysics, University of Rochester School of Medicine, 601 Elmwood Ave, Rochester, NY 14642, United States^c Aab Institute of Cardiovascular Sciences, University of Rochester School of Medicine, 601 Elmwood Ave, Rochester, NY 14642, United States^d Department of Pharmacology, University of California at San Diego, 9500 Gilman Dr – MC 0636, La Jolla, CA 92093, United States^e Department of Medicine, SUNY Upstate Medical University, 4310 Institute for Human Performance, 750 East Adams St, Syracuse, NY 13210, United States

ARTICLE INFO

Article history:

Received 3 January 2012

Accepted 13 January 2012

Available online 20 January 2012

Keywords:

Phospholipase C ϵ

G protein-coupled receptor

Ras family GTPase

Cardiovascular function

Diabetes

Inflammation

ABSTRACT

Receptor-initiated phospholipase C activation and generation of IP₃ and DAG are important common triggers for a diversity of signal transduction processes in many cell types. Contributing to this diversity is the existence and differential cellular and subcellular distribution of distinct phospholipase C isoforms with distinct regulatory properties. The recently identified PLC ϵ enzyme is an isoform that is uniquely regulated by multiple upstream signals including ras-family GTP binding proteins as well as heterotrimeric G-proteins. In this review we will consider the well documented biochemical regulation of this isoform in the context of cell and whole animal physiology and in the context of other G protein-regulated PLC isoforms. These studies together reveal a surprisingly wide range of unexpected functions for PLC ϵ in cellular signaling, physiology and disease.

© 2012 Elsevier Inc. All rights reserved.

Contents

1. Introduction	1334
1.1. PLC overview	1334
1.2. PLC isoforms and general regulatory properties	1334
2. PLC ϵ structure and regulatory properties	1335
2.1. PLC ϵ discovery	1335
2.2. PLC regulation in transfected cells	1335
2.3. Mechanisms of activation of PLC ϵ	1335
2.4. Feed forward regulation of PLC ϵ activity by Rap GEF	1336
2.5. Role of PLC ϵ in IP ₃ and DAG formation	1337
3. Physiological roles of PLC ϵ revealed in PLC ϵ deficient mice	1337
3.1. PLC ϵ in cardiac function	1337
3.1.1. Semilunar valve development	1337
3.1.2. Cardiomyocyte hypertrophy	1337
3.1.3. Cardiac myocyte contraction	1338
3.1.4. Scaffolding of PLC ϵ in the heart	1339
3.2. Role of PLC ϵ in pancreatic β cell function	1340
3.3. PLC ϵ in inflammation and cancer	1341

Abbreviations: PLC, phosphoinositide-specific phospholipase C; PKC, protein kinase C; LPA, lysophosphatidic acid; SIP, sphingosine-1 phosphate; Epac, Exchange protein directly activated by cAMP; GPCR, G protein-coupled receptor; GEF, guanine nucleotide exchange factor; EGF, epidermal growth factor; PDGF, platelet-derived growth factor; Iso, Isoproterenol; PKD, protein kinase D; RA, Ras association domain; IP, inositol phosphate; DAG, diacylglycerol; PIP₂, phosphatidylinositol 4,5 bisphosphate; IP₃, inositol 1,4,5 triphosphate; NRVM, neonatal rat ventricular myocyte; AVM, adult ventricular myocyte; IGF-1, insulin-like growth factor 1; ET-1, endothelin-1; CICR, calcium-induced calcium release; PKA, protein kinase A; cpTOME, 8-(4-chloro-phenylthio)-2'-O-methyladenosine-3'-5'-cyclic monophosphate; AKAP, A kinase anchoring protein; 2-APB, 2-aminophenyl borate; RyR, ryanodine receptor; CaMKII, calcium calmodulin-dependent kinase II; SR, sarcoplasmic reticulum; GSIS, glucose-stimulate insulin secretion; T2DM, type 2 diabetes mellitus; GLP-1, glucagon-like peptide-1; TPA, 12-O-tetradecanoylphorbol-13-acetate; VEGF, vascular endothelial growth factor; SNP, single nucleotide polymorphism; ESCC, esophageal squamous cell carcinoma

* Corresponding author. Tel.: +1 585 275 0892; fax: +1 585 273 2653.

E-mail addresses: Alan_Smrcka@urmc.rochester.edu (A.V. Smrcka), jhbrown@ucsd.edu (J.H. Brown), holz@upstate.edu (G.G. Holz).

4. Roles for PLC ϵ in human disease	1341
4.1. PLC ϵ in the kidney	1341
4.2. PLC ϵ in esophageal cancer and gastric adenocarcinoma	1342
5. Conclusion and outlook	1342
Acknowledgments	1342
References	1342

1. Introduction

1.1. PLC overview

Receptor-stimulated hydrolysis of phosphatidylinositol 4,5 bisphosphate (PIP₂) to generate inositol 1,4,5 trisphosphate (IP₃) and diacylglycerol (DAG) is a fundamental signaling process in the biology of virtually all mammalian cells and in many lower eukaryotes. The proteins that catalyze this reaction are the phosphoinositide-specific phospholipase Cs (PLCs), which function at key control points for directing signaling responses to a variety of regulatory stimuli [26,27,59,75] (Fig. 1). The immediate consequences of this reaction are manifold and are initiated through two canonical signaling pathways downstream: regulation of Ca²⁺ release into the cytoplasm from intracellular endoplasmic reticulum stores, and activation of protein kinase C (PKC) cascades. Additionally, PIP₂ is a signaling molecule in its own right, most notably as a stabilizer of ion channel activity, with PIP₂ depletion serving as a mechanism for the regulation of channel activity [30,74,76]. All of these processes have the potential to dramatically alter cellular physiology and contribute to cellular pathophysiology.

There are multiple PLC isoforms that are differentially localized and regulated, enabling them to participate in a variety of distinct physiological processes. This review will focus on emerging physiological and pathophysiological roles for one recently identified isoform of PLC, PLC ϵ . PLC ϵ is unique in relation to other phospholipase C isoforms in terms of its ability to be regulated by multiple signaling inputs from both Ras family GTPases and heterotrimeric G proteins. In addition, it contains a small GTPase nucleotide exchange factor domain that serves to function in activating Ras family GTPases. Thus, PLC ϵ has the capacity to respond to, and integrate diverse cellular information as well as participate in more sustained signal generation. In this review, we will discuss how biochemically defined cellular signaling mechanisms both upstream and downstream of PLC ϵ function to regulate specific physiological functions.

1.2. PLC isoforms and general regulatory properties

The family of phospholipase C enzymes includes 13 different isozymes grouped into 6 different classes based on sequence homology (Fig. 1B and C). All phospholipase C isoforms contain highly conserved X




Fig. 1. Phospholipase C isoforms. A) Reaction catalyzed by PI-PLC and overall structure. Structure of PLC β 2 (Protein Database ID: 2ZKM) taken from [29] and rendered with Molsoft ICM. The catalytic domain comprised the X and Y domains is in red, the Pleckstrin Homology (PH) domain is in blue, the EF hand domain is in yellow and the C2 domain is in purple. B) PLC isoforms with domains color coded as in panel A. C) Two splice variants of PLC ϵ which include in addition to the aforementioned common domains, 2 ras association homology (RA) domains and a CDC25 homology guanine nucleotide exchange factor (GEF) domain.

and Y domains that fold to form the catalytic core of the enzyme, a phospholipid binding C2 domain, and an EF hand domain [21,26,27,59,75] (Fig. 1A, B and C). Outside of the core conserved regions, there is diversity in protein structure that reflects the range of mechanisms utilized for regulation of these enzymes, and that underlies the basis for classification of the different groups. There are 4 members of the β class, 2 members of the γ class and 3 members of the δ class. These groupings also correspond to functional classifications. Members of the PLC γ class are regulated by receptors that are coupled to tyrosine kinases [9,51,59]. Members of the PLC β class are activated by G protein subunits [8,69,70,79,82]. PLC δ activation mechanisms are less well defined, but its unusual sensitivity to Ca²⁺ puts it in a position to amplify Ca²⁺ responses initiated by other PLC isoforms [58] or other mechanisms [80]. PLC ζ , comprises a class of enzyme localized to sperm and it is involved in fertilization [77]. PLC η is a neuron-specific class whose function has yet to be defined, but it appears to be regulated by G protein $\beta\gamma$ subunits [52,91].

2. PLC ϵ structure and regulatory properties

2.1. PLC ϵ discovery

The first identification of a PLC ϵ homologue was in a yeast two-hybrid screen of a *Caenorhabditis elegans* library with a *C. elegans* Ras homologue LET-60 as the bait [65]. This 210 kDa protein, PLC210, was shown to bind Ras and possess PLC activity. Subsequently, mammalian isoforms of PLC210 were independently identified and cloned by three groups using homology based screening of human and rat EST databases [43,47,71]. The PLC210 and PLC ϵ clones were highly homologous, and contained Ras association (RA) homology domains and, surprisingly, a putative small GTPase nucleotide exchange factor domain (Fig. 1C). Subsequently, two forms of PLC ϵ were found to arise from alternative splicing at the amino terminus. These are designated as PLC ϵ 1a and PLC ϵ 1b, and they differ in size by 25 kDa [73] (Fig. 1C). No functional differences between the two splice variants have as yet been identified.

Analysis of the PLC ϵ mRNA content of various tissues/organs by either northern blot [43,47] or reverse transcriptase PCR [73] suggests a relatively widespread distribution of both spliced transcripts, although there are some differences in splice variant distributions. Analysis by immunoblotting has proven to be more challenging even though relatively strong antibodies for PLC ϵ detection have been developed [85]. In many tissues PLC ϵ is not readily detectable by direct immunoblotting, but rather requires an immunoprecipitation step from tissue lysates to enrich the PLC ϵ protein prior to immunoblotting ([85,90], and unpublished observations). These observations have led to the suggestion that PLC ϵ protein is present in low abundance in most tissues and cell types and at significantly lower levels than other PLC isoforms, although a systematic quantitative analysis supporting this idea is lacking.

2.2. PLC regulation in transfected cells

Since the initial demonstration that PLC ϵ can be activated by Ras in transfected cells [43,71], it has become clear PLC ϵ can be activated by a wide variety of protein partners (Table 1). These include members of the Ras family such as Rap1, Rap2, TC21, Ral, Rho and Rac as well as the heterotrimeric G protein subunits G α_{12} , G α_{13} , and $\beta\gamma$ [36,44,47,63,88]. Thus receptors that either directly or indirectly regulate these G proteins have the potential to regulate PLC ϵ (Fig. 2) (Table 2). For example, G protein-coupled receptors (GPCRs) that bind lysophosphatidic acid (LPA), sphingosine-1-phosphate (S1P), and thrombin (PAR) activate recombinant PLC ϵ heterologously expressed in COS-7 cells [24], or endogenous PLC ϵ in Rat1 fibroblasts [44]. Blocking G $\alpha_{12/13}$, Gi, or Rho activation could inhibit activation of PLC ϵ depending on the receptor being tested [24,44]. Thus, individual G-protein coupled receptors appear to use distinct signaling pathways to activate PLC ϵ .

Table 1
Phospholipase C ϵ activators.

Direct binding to PLC ϵ	PLC ϵ domain that binds	Assays/tools	Reference
Rho	Y-domain insert required for Rho-dependent activation but does not bind Rho RA2 domain	In vitro reconstitution purified Y domain deletion	[63]
H-Ras		GST-pulldown, ITC, ^a cotransfection enzyme activation assay ^b	[43] [7]
K-Ras, N-Ras	RA2 domain	GST-pulldown	[7]
R-Ras	RA2 domain	GST-pulldown, ITC	[7]
Rap1A&B	RA2 domain	GST-pulldown, ITC, cotransfection enzyme activation assay	[44] [7]
Rap2A	RA2 domain	GST-pulldown, ITC, cotransfection enzyme activation assay	[44] [7]
Ral	?, not RA dependent	GST-pulldown, cotransfection enzyme activation assay	[44]
Rac	?, not RA dependent	GST-pulldown, cotransfection enzyme activation assay	[44]
TC21	RA2 domain	GST-pulldown, cotransfection enzyme activation assay	[44] [7]
Indirect activation of PLC ϵ			
G $\alpha_{12/13}$?	Cotransfection enzyme activation assay, RGS inhibition	[44] [47]
$\beta\gamma$?	Cotransfection enzyme activation assay, GRK2 ct	[88]

^a Isothermal titration calorimetry.

^b Activator and PLC ϵ transfected into cells and total inositol phosphates were measured.

Interestingly, in HEK293 cells, agonist stimulation of recombinant β_2 adrenergic receptors activated PLC ϵ in a cAMP, Epac (exchange protein directly activated by cAMP) and Rap GTPase-dependent manner [61]. Epac is a cAMP-regulated guanine nucleotide exchange factor that can activate Rap which in turn binds directly to PLC ϵ , thereby stimulating the phospholipase. Growth factor-activated receptor tyrosine kinases were also shown to stimulate PLC activity in cell lines transfected with recombinant PLC ϵ [71,72]. These studies in various biochemical systems and cell lines laid the groundwork for further elucidating how PLC ϵ participates in signal transduction pathways downstream of multiple GPCR and growth factor receptors. This information is critical to understanding how PLC ϵ participates in distinct physiological and pathophysiological responses.

2.3. Mechanisms of activation of PLC ϵ

Direct interactions of upstream regulators with PLC ϵ can be divided into 2 general classes: those that interact directly with the phospholipase's second Ras association homology domain (RA2 domain) on PLC ϵ , and those that bind elsewhere in the PLC ϵ protein [44]. For example Ras and Rap bind directly to the RA2 domain while Rho, Ral and G $_{12/13}$ do not. The site on PLC ϵ required for Rho-dependent activation is an insert in the catalytic domain unique to PLC ϵ [63]. Thus, similar to other PLCs, different regions of the enzyme are involved in interactions with different upstream activators. It is not clear that regulators such as G $_{12/13}$ and G $\beta\gamma$ bind directly to PLC ϵ . Indeed, G $\alpha_{12/13}$ activation of PLC ϵ is not likely to be direct but rather appears to occur through p115 RhoGEF or other RhoGEFs catalyzing the activation of RhoA which in turn binds directly to PLC ϵ to activate it [24].

How direct binding of various G protein regulators to any PLC isoform leads to increased PLC activity remains unclear despite the emergence of new structural data for complexes of PLC β with G-proteins [29,49,83].




Fig. 2. Common mechanisms for PLC ϵ regulation of CICR in cardiac myocytes and pancreatic β cells downstream of Gs-coupled receptors. A) Common upstream components regulate of PLC ϵ by Gs coupled receptors in adult cardiac myocytes and isolated pancreatic β cells [19,54]. B) Signaling downstream of PLC ϵ . In red are components found to be involved in regulation of CICR in both cardiac myocytes and pancreatic β cells [19,54]. An alternative pathway has also been proposed and is depicted in black and may operate in β cells as well [57].

One mechanism could involve translocation of cytosolic PLCs to the membrane where they would gain access to the PIP $_2$ substrate. Additionally, it has been proposed, based on structural information from PLC β , that membrane association can remove an auto-inhibitory element, common to all PLC isoforms, from the PLC catalytic core and thereby lead to activation [27,29]. In COS-7 cells, transfection with activated Ras or Rap causes translocation of GFP-PLC ϵ from the cytosol to membranes. Ras promotes plasma membrane association of PLC ϵ [71] while Rap promotes translocation of PLC ϵ to perinuclear regions such as the Golgi apparatus [36]. Epidermal growth factor (EGF) also promotes translocation to plasma or Golgi membranes, dependent on Ras or Rap1 activation respectively [36,71]. Together, these data suggest that translocation from cytosol to membrane may, in part, underlie the mechanism for activation of PLC ϵ . However, membrane targeting is not the only factor driving activation. Directing overexpressed PLC ϵ to the membrane by appending a membrane targeting CAAX sequence at the C terminus of PLC ϵ leads increased activity relative to a non-membrane targeted PLC ϵ , but expression of Ras or stimulation with

EGF further increases the activity of the CAAX modified PLC ϵ [7]. These data indicate that while membrane targeting may be part of the activation mechanism, additional physical alterations of the enzyme at the membrane surface occur upon interaction with Ras or other activators.

2.4. Feed forward regulation of PLC ϵ activity by Rap GEF

In addition to its PIP $_2$ hydrolytic activity, PLC ϵ has a CDC25 homology domain suggesting a putative guanine nucleotide exchange factor (GEF) function (Fig. 1C). There are conflicting reports concerning the activity of this domain in PLC ϵ . One study suggested that PLC ϵ may be a GEF for Ras, but the evidence is indirect [47]. In a separate study, Rap1A, but not Ras was a substrate for PLC ϵ GEF in an in vitro assay with purified components [36]. Similarly, recombinant PLC ϵ stimulated formation of RapGTP but not RasGTP in transfected COS-7 cells. In astrocytes from PLC ϵ KO mice, hormonal activation of Rap was diminished while that of Ras was not [13], as detailed below. The cell biological function of the CDC25 domain in PLC ϵ has been investigated extensively by the Kataoka group. Expression of PLC ϵ or the CDC25 domain led to activation of the Rap effector pathways B-Raf and ERK. Sustained, but not acute, EGF receptor-dependent activation of Rap was enhanced by PLC ϵ but only if it contained an intact CDC25 domain. Similarly EGF and Rap-dependent translocation of PLC ϵ to the Golgi apparatus were independent of the CDC25 domain at short times of stimulation but sustained Golgi association was shown to be CDC25 domain-dependent [36]. The model suggested by these data is that Rap localization at the Golgi drives PLC ϵ to the Golgi where it has access to substrate. PLC ϵ in turn activates Rap which serves to reinforce PLC ϵ association with Golgi and maintain the signal at the membrane. Similarly, PLC ϵ CDC25 activity is required for the sustained activation of PLC ϵ activity in a stable cell line expressing the PDGF receptor [72]. These data reinforce the concept that activated Rap generated by the PLC ϵ CDC25 domain feeds forward to PLC ϵ by binding the RA2 domain to maintain PLC activation.

Further support for the idea that PLC ϵ is a Rap GEF in a physiological setting comes from studies of Rap activation in primary cells or tissues isolated from PLC ϵ knockout mice. In astrocytes isolated from PLC ϵ knockout mice, thrombin-stimulated sustained Rap activation was significantly decreased compared to wild type mice, while thrombin-stimulated Ras activation was unaffected by PLC ϵ deletion [13]. Similarly in isolated mouse hearts, perfusion with isoproterenol (Iso) stimulated Rap activation in a manner that was completely lost in PLC ϵ null mice [53]. The bioactive lysophospholipid S1P also activates Rap1 in the

Table 2

Ligands/receptors shown to couple to phospholipase C ϵ activation.

Ligands/receptor ^a	Cell type	Signaling mechanism
GPCRs LPA/Edg	Astrocytes	Gi/G β γ [13]
	Cos-7	G $_{12/13}$ /Rho [44]
	Rat-1 fibroblasts	? [42]
Thrombin/PAR	Astrocytes	G $_{12/13}$ /Rho [13]
	Cos-7	G $_{12/13}$ /Rho [44]
	Rat-1 fibroblasts	? [42]
S1P/Edg	Astrocytes	Gi/G β γ [13]
	Cos-7	G $_{12/13}$ /Rho [44]
Endothelin/ET-1R	Rat-1 fibroblast	? [42]
	NRVM ^b	? [90]
Isoproterenol/ β -adrenergic receptor	NRVM	Gs/cAMP/Epac1/Rap [90]
	AVM ^c	Gs/cAMP/Epac1/Rap [54]
	HEK293	Gs/cAMP/Epac1/Rap [61]
Exendin-4/GLP-1R	Pancreatic β cells	Gs/cAMP/Epac2/Rap [20]
Tyrosine kinases EGF/EGF-R	COS-7	Ras [71]
		[44]
		[72]
PDGF/PDGF-R	BaF3	[72]
IGF-1/IGF-1-R	NRVM	? [90]

^a In most cases the specific receptor subtypes have not been defined.

^b Neonatal rat ventricular myocytes.

^c Adult mouse ventricular myocytes.

isolated mouse heart and this effect is diminished in PLC ϵ knockout mice (Xiang et al., in preparation). In astrocytes, PLC ϵ knockout eliminates the sustained phase of ERK activation that can be rescued by re-expression of PLC ϵ but not with re-expression of PLC ϵ with a mutation that disables the GEF domain of PLC (Δ CDC25 PLC ϵ) [13]. Finally, in cardiac myocytes isolated from PLC ϵ knockout mice, isoproterenol regulation of cardiac calcium cycling is impaired, but can be rescued by expression of wild-type (wt) PLC ϵ but not Δ CDC25 PLC ϵ [53]. These data suggest that PLC ϵ GEF activity is important for sustained Rap activity in maintaining calcium cycling. Since PLC ϵ activity involved in the regulation of cardiac contraction (as discussed below) we propose that Rap also activation generates a feed-forward amplification signal that maintains sustained PLC ϵ activity at specific sites in cardiac myocytes, such as at the sarcoplasmic reticulum. Rap activation may also serve to signal to other pathways such as observed for sustained ERK activation in isolated astrocytes [13], and activation of PKD in isolated astrocytes (Dusaban, in preparation).

2.5. Role of PLC ϵ in IP $_3$ and DAG formation

Given the multiple direct activators of PLC ϵ it stands to reason that PLC ϵ can be a central integrator of multiple upstream signals. As discussed above, PLC ϵ can be activated by both GPCRs and receptor tyrosine kinases [24,36,44]. This raises the question as to the role of PLC ϵ in generating signals relative to other PLCs such as PLC β and PLC γ that are well established as major mediators of PIP $_2$ hydrolysis downstream of GPCRs and tyrosine kinase signaling, respectively [59]. Studies knocking down PLC ϵ in cultured cells or genetically deleting PLC ϵ in higher organisms such as mice have begun to shed light on this. In an initial study in Rat1 fibroblasts, siRNA knockdown of endogenous PLC ϵ vs. PLC β 3 had different temporal effects on IP production downstream of receptor activation [42]. In general, knockdown of PLC β 3 significantly reduced short term IP generation (<3 min) whereas knockdown of PLC ϵ did not significantly affect this response. Conversely, knockdown of PLC ϵ significantly reduced longer term IP accumulation (3–60 min) in a manner that was unaffected by PLC β 3 knockdown. Although these effects were somewhat dependent on the receptor being tested, they are understandable if PLC ϵ is responsible for sustained PIP $_2$ hydrolysis, consistent with the model discussed above whereby Rap1 activation by the PLC ϵ -CDC25 domain can sustain PLC ϵ activity. It is important to note that these assays of IP $_3$ production are indirect in that they measure levels of inositol-1P generated from the metabolism of inositol phosphates. The lifetime of IP $_3$ in receptor-stimulated assays where IP $_3$ is measured is generally very short with most of the IP $_3$ generated in the first minute after receptor stimulation and back to baseline within 1 or 2 min, although this can be receptor dependent. Thus during the sustained phase of IP production the level of IP $_3$ that accumulates is generally quite low. This suggests that a major function of PLC ϵ is to control longer term processes requiring sustained phosphoinositide hydrolysis, but perhaps involving DAG rather than IP $_3$ as a major product.

An understanding of the contributions of PLC ϵ signaling downstream from various receptors, relative to other PLC isoforms, has also arisen from studies of PLC ϵ knockout mice. For example, IP production downstream of various receptors was examined in astrocytes isolated from PLC $\epsilon^{+/+}$ and PLC $\epsilon^{-/-}$ mice [13]. These studies revealed a large percentage of the total IPs generated by S1P, thrombin or LPA were dependent on the presence of PLC ϵ while IP generation stimulated by carbachol, which acts on the G $_q$ coupled muscarinic receptor, was unaffected. In the case of thrombin, longer term IP generation was significantly reduced in the PLC ϵ knockout but in the case of carbachol, IP generation was not attenuated at any time in the PLC ϵ knockout cells. In considering the receptors involved, and the possible G proteins they activate it is important to note that LPA, thrombin and S1P all activate GPCRs coupled to G $_q$ as well as G $_{12/13}$ and in some cases G $_i$. In contrast, the muscarinic receptors in these cells are thought to couple purely to G $_q$. In these studies, C3 exoenzyme and pertussis toxin were used to block

RhoA and G $_i$ signaling respectively and indicate that PLC ϵ activation by S1P and LPA was strongly dependent on G $_i$ while thrombin signals to PLC ϵ through RhoA, likely in a G $_{12/13}$ -dependent manner. Thus each receptor uses a unique pathway to couple PLC ϵ activation to IP production. Finally, it is noteworthy that in neonatal rat ventricular cardiac myocytes, inositol phosphate generation by the G $_q$ -coupled, hypertrophic receptors for ET-1 and norepinephrine were unaffected by PLC ϵ knockdown, but hypertrophic responses to these agonists were ablated [90]. In contrast S1P, which does not produce cardiomyocyte hypertrophy, induced modest inositol phosphate production in these cells, through G $_{12/13}$ coupling to RhoA and is inhibited by PLC ϵ knockdown (Xiang et al., in preparation). These findings suggest that distinct pools of phosphoinositides are under the control of PLC ϵ with some required for the hypertrophic response and others serving other functions.

3. Physiological roles of PLC ϵ revealed in PLC ϵ deficient mice

While the data discussed above reveal detailed signaling mechanisms involved in PLC ϵ regulation and cellular function, many of the physiological functions for PLC ϵ have emerged from studies of PLC ϵ knockout animals produced independently in two laboratories (known physiological functions are summarized in Table 3). The phenotypes of these two animals do not entirely overlap in part because the laboratories involved have taken their studies in different directions, but also because the nature of the knockouts are not identical. Tohru Kataoka's laboratory generated a mouse lacking a portion of the EF-hand and the catalytic domain (PLC $\epsilon^{\Delta x/\Delta x}$) [78]. As a result, a shortened version of PLC ϵ is produced that is catalytically inactive with respect to PIP $_2$. The knockout generated in our laboratory deleted the first common exon 6 in the PLC ϵ gene resulting in complete loss of detectable PLC ϵ protein [85]. Thus it might be expected that the phenotypes of these animals would differ significantly.

3.1. PLC ϵ in cardiac function

3.1.1. Semilunar valve development

Interestingly both the PLC $\epsilon^{\Delta x/\Delta x}$ and PLC $\epsilon^{-/-}$ mice have cardiac defects but the nature of these defects is different. PLC $\epsilon^{\Delta x/\Delta x}$ mice have enlarged hearts resulting from ventricular dilation that occurs over the course of development that does not result from cardiac myocyte hypertrophy [78]. PLC $\epsilon^{-/-}$ mice do not have enlarged hearts but have an increased susceptibility to hypertrophy development in response to adrenergic stress [85] (this phenotype will be discussed in greater depth below). In the PLC $\epsilon^{\Delta x/\Delta x}$ mice, the ventricular dilation results from aberrant development of the aortic and pulmonary semilunar valves manifest as thickening and stiffening of the valves [78]. This increases valvular regurgitation resulting in chronic volume overload which is likely the cause of the ventricular dilation. The defects in valvulogenesis observed in these mice are reminiscent of the phenotype observed in mice with defects in HB-EGF or the EGF receptor. Since the EGF receptor could potentially signal to PLC ϵ through the activation of Ras or Rap, the authors speculate that the phenotype is due to a defect in the ability of EGF to generate the appropriate signals from PLC ϵ . Interestingly there is an increase in the levels of phospho-SMADs in the valves of the PLC $\epsilon^{\Delta x/\Delta x}$ mice and it has been suggested that SMADs play an important role in valve cell proliferation [62]. It is nonetheless unclear what PLC ϵ -dependent signals would lead to alterations in SMAD regulation. Furthermore, the pathway that underlies potential EGF-dependent regulation of PLC ϵ activation remains to be elucidated.

3.1.2. Cardiomyocyte hypertrophy

PLC $\epsilon^{-/-}$ mice do not develop spontaneous hypertrophy. However, when exposed to a chronic adrenergic stimulation resulting from chronic delivery of isoproterenol for one week, PLC $\epsilon^{-/-}$ mice develop significantly greater hypertrophy than PLC $\epsilon^{+/+}$ mice [85]. In addition, PLC ϵ mRNA increases during aortic banding of the wt mice and is

Table 3
Summary of physiological roles for PLC ϵ signaling.

	System(s)	Signaling	Functional role	References
Cardiac				
Contractility	Knockout mouse; AVM	β AR/cAMP/Epac/Rap/ PLC ϵ /PKC/CaMKII/RyR2	Increases contractility	[85]; [54]
Hypertrophy	Knockout mouse; NRVM	Downstream of ET-1, β -AR, α 1-AR, IGF1-R	Knockout animal suggests PLC ϵ suppresses hypertrophy but NRVM siRNA suggests PLC ϵ mediates hypertrophy	[85]; [90]
Valve development	Knockout mouse	EGF signaling		[78]
Pancreas				
β -cell Ca ²⁺ handling	Knockout mouse	GLP1R/cAMP/Epac/Rap/PLC ϵ /PKC/CaMKII/RyR or IP ₃ -R	Enhances cAMP-dependent CICR	[19]
Insulin release	Knockout mouse	Presumably the same as for β -cell calcium handling	Mediates cAMP-potentiation of insulin release	[20]
Cancer/inflammation				
Epidermal squamous cell tumors	Knockout mouse	TPA induced Rap GEF activation/PLC ϵ ?/production of inflammatory mediators	Pro-inflammatory action enhances tumor formation	[3]
Allergic contact sensitivity	Knockout mouse; PLC ϵ transgenic	?/PLC ϵ ?/production of inflammatory mediators	Pro-inflammatory	[33]
Esophageal cancer	GWAS	?	PLC ϵ SNPs positively associated with Esophageal cancer and gastric adenocarcinoma	[1,86]
Kidney disease				
Childhood nephrotic syndrome	Human genetic analysis	Expressed highly in glomerular podocytes	May be involved in glomerular development but knockout mouse has no glomerular defect	[31]
Brain				
Astrocyte proliferation	Knockout mouse	Thrombin/G _{12/13} /rho/PLC ϵ /Rap/B-RAF/ERK	Regulates DNA synthesis in response to thrombin	[13]

elevated in tissue samples from human heart failure patients. To investigate the specific cellular signaling mechanism by which PLC ϵ regulates cardiac hypertrophy we studied neonatal rat ventricular myocytes (NRVMs) in which PLC ϵ was knocked down using siRNA. Hypertrophic responses to many neurohumoral agonists can be observed in this model [66–68], thus it was possible to examine stimulation of hypertrophy by a variety of agonists that signal through different pathways [90]. Surprisingly, all of the stimuli tested required the presence of PLC ϵ to elicit a hypertrophic response. These stimuli included: 1) Iso, which acts through β adrenergic stimulation of Gs and cAMP, 2) endothelin-1 through ET receptors coupled to G_q, G_{12/13} and/or G_i, 3) norepinephrine through α 1-adrenergic receptors and G_q, and 4) IGF-1, through tyrosine kinase linked signaling likely activating either Ras or Rap1. The exact mechanisms by which these ligands signal through or require PLC ϵ has not yet been determined, but the ability of PLC ϵ to mediate the hypertrophic response to such varied upstream regulatory molecules identifies PLC ϵ as a nexus for responding to multiple upstream signals in cardiac cells.

While the data regarding the role of PLC ϵ in the hypertrophic response of NRVMs is clear, several important issues remain unresolved. As discussed above, PLC ϵ ^{-/-} mice are more susceptible to hypertrophy, but in NRVMs the opposite result is seen i.e. PLC ϵ deletion protects against hypertrophy. One potential explanation for this discrepancy is that the PLC ϵ ^{-/-} mice have PLC ϵ deleted globally during development, thus compensatory changes and global effects from other cell types can impact the in vivo phenotype. Alternatively, this could be explained by a difference between a cell biological model of hypertrophy based on NRVMs and a whole animal model examining the adult mouse. Resolving this issue will require a more sophisticated gene deletion strategy in which PLC ϵ expression is deleted conditionally, after development and specifically in cardiac myocytes. A second issue concerns the role of G α_q in hypertrophic signaling. G α_q overexpression stimulates hypertrophy of NRVMs in vitro [2] and transgenic G α_q overexpression in the heart leads to development of hypertrophy and heart failure [14]. Mice with conditional cardiac myocyte specific deletion of both G α_q and G α_{11} do not develop hypertrophy in response to pressure overload (transverse aortic constriction or “banding”) [87]. Thus, G α_q signaling is essential for the development of pathological forms of hypertrophy which

transition to heart failure. G_q regulates PLC β and does not directly regulate PLC ϵ . Furthermore, a splice variant of PLC β 1 was recently shown to be critical for hypertrophy downstream of G α_q in NRVMs [22]. Unpublished data from our own laboratory using PLC ϵ siRNA in NRVMs shows that PLC ϵ is essential for G α_q -dependent hypertrophy, as it is for responses to multiple agonists. A model that would reconcile these data would be that both PLC β and PLC ϵ are necessary for G α_q -dependent hypertrophy, with PLC β being activated directly by G α_q , and PLC ϵ being activated as an indirect consequence of G α_q signaling through an as yet unknown mechanism. Since these enzymes both have the same activities, there must be spatiotemporal differences in their function that allows each to provide signals required for the hypertrophic response.

3.1.3. Cardiac myocyte contraction

In addition to showing alterations in hypertrophic responsiveness, PLC ϵ ^{-/-} mice showed defective ionotropic responses to β -adrenergic stimulation [85]. At baseline, PLC ϵ ^{-/-} and PLC ϵ ^{+/+} mice had similar heart rates and did not differ in contractile function (dP/dT, a measure of the force of contraction). Isoproterenol (Iso)-induced changes in heart rate were no different in the two sets of animals but the Iso-dependent increase in contractile force (dP/dT) was significantly blunted in the PLC ϵ knockout mice. To investigate the nature of this defect, adult ventricular myocytes (AVM) were isolated from PLC ϵ ^{-/-} mice and analyzed for alterations in Iso-dependent increases in depolarization induced Ca²⁺-induced Ca²⁺ release (CICR; note that the amplitude of CICR in cardiac myocytes determines in part the force of contraction by enhancing actin–myosin crossbridging). This analysis revealed that AVMs isolated from PLC ϵ ^{-/-} mice had diminished Iso-dependent increases in CICR. Thus, PLC ϵ in AVMs appears to play an important role to enable β AR-dependent regulation of cardiac CICR and contraction. Since β -adrenergic regulation of cardiac contractility has been widely shown to be controlled by cAMP-dependent regulation of PKA-mediated phosphorylation events [5], a role for PLC activity in this process was unexpected.

To understand the molecular basis for this contractility defect in the hearts of PLC ϵ knockout mice, and to understand the function of PLC ϵ in the regulation of CICR, many questions concerning the signaling mechanisms upstream and downstream of PLC ϵ needed to be clarified.

First, previous work had not demonstrated β -adrenergic stimulation of IP production in cardiac myocytes, and since β adrenergic receptors are coupled to G_s , a mechanism for PLC regulation by these receptors in the heart was not immediately clear. A clue came from studies of PLC ϵ signaling in HEK293 cells showing that the cAMP-dependent Rap exchange factor Epac could activate PLC ϵ through Rap2B activation [61]. Surprisingly, direct stimulation of AVMs with an Epac activator, 8-(4-chloro-phenylthio)-2'-O-methyladenosine-3'-5'-cyclic monophosphate (cpTOME), caused an increase in CICR that was completely absent in the PLC ϵ knockout mice [54]. Responsiveness to cpTOME could be restored by adenoviral re-expression of PLC ϵ in AVMs isolated from PLC $\epsilon^{-/-}$ mice, but not by re-expression of a catalytically dead PLC ϵ . These data indicated that a pathway downstream of the β -adrenergic receptor involves cAMP-dependent activation of Epac which in turn, produces activated Rap which directly stimulates PLC ϵ activity (Fig. 2A). Interestingly, expression of PLC ϵ lacking a portion of the GEF domain did not rescue Epac-dependent regulation of CICR, suggesting that PLC ϵ GEF activity is required for maintenance of Rap activation by Epac which is, in turn, required to sustain PLC ϵ dependent regulation of CICR [53]. Under conditions of strong β -adrenergic receptor activation, the Epac/PLC ϵ pathway appeared to account for about half of the increase in CICR induced by activation of the β -adrenergic receptor. As discussed below, the reason that IP production is not observed upon β -adrenergic receptor stimulation may be because PLC ϵ activity is restricted to discreet regions, or that relatively low but sustained PI hydrolysis that occurs upon PLC ϵ activation in myocytes is not readily detected in assays for IP production.

A second question is how the products of PLC ϵ activity regulate CICR and cardiac contraction. Prior to the above-mentioned studies, no mechanistic pathways for PLC regulation of CICR in the heart had yet been described. In cardiac myocytes the major determinants of CICR are the sarcolemmal L-type calcium channels and the type2 ryanodine receptors (RyR2) in the sarcoplasmic reticulum [5]. The classical effectors downstream of PLC activation are IP $_3$ receptors and PKC. IP $_3$ receptors are in very low abundance in the ventricular cardiac myocytes and are not thought to play a major role in ventricular CICR [17]. Treatment of AVMs with 2-APB, a blocker of IP $_3$ receptors, did not affect Iso or Epac-dependent CICR in these studies [53]. A PKC inhibitor, on the other hand, partially blocked Iso-dependent regulation of CICR and completely blocked Epac-dependent enhancement of CICR [53]. Iso and Epac also induced activation of a single PKC isoform, PKC ϵ , and PKC ϵ siRNA inhibited Epac-dependent increases in CICR. PKC activity had not been directly implicated in the regulation of cardiac Ca $^{2+}$ transients. However, a clue came from a study by Pereira et al. indicating that activation of Epac could stimulate CaMKII-dependent phosphorylation of RyR2 [56]. We determined that PKC inhibition also blocked Epac-dependent CaMKII-autophosphorylation and phosphorylation of downstream targets [53]. This data allowed us to more completely model a pathway in which the role for PLC ϵ was in activation of PKC downstream of Iso stimulation and subsequent activation of CaMKII and phosphorylation of RyR2 to regulate CICR [53] (Fig. 2B in red). Loss of this mechanism likely underlies, at least in part, the decreased ability of Iso to stimulate cardiac contraction in PLC $\epsilon^{-/-}$ mice. A later study showed that Epac stimulation leads to an increase in the sensitivity of cardiac myofilaments to Ca $^{2+}$ [10]. This also appeared to require PKC and CaMKII activation, thus while not directly demonstrated, may also be mediated through activation of PLC ϵ by Epac.

An alternative view for the mechanisms of Epac-dependent regulation of RyR2 in cardiac myocytes has been proposed in another recent study [57]. In this study, a role for PLC in Epac-dependent regulation of RyR2 was proposed based on the use of the PLC inhibitor, U73122. However, treatment with a PKC inhibitor did not influence Ca $^{2+}$ release through RyR2 whereas the effect of Epac activation on Ca $^{2+}$ release from RyR2 was blocked by 2-APB. Since IP $_3$ receptors are localized to the nuclear envelope in ventricular cardiac myocytes the authors propose that Ca $^{2+}$ release through IP $_3$ receptors near the nucleus locally

activates CaMKII which in turn phosphorylates RyR2 in the SR leading to enhanced Ca $^{2+}$ release (Fig. 2B in black). The complete lack of effect of a PKC inhibitor and full effect of an IP $_3$ receptor antagonist on these responses is difficult to reconcile with the study by Oestreich et al. where PKC effects were rigorously demonstrated in mouse AVMs at multiple levels: a PKC inhibitor, measurements of Epac-dependent PKC activation, and isoform-specific PKC ϵ siRNA. Also the IP $_3$ receptor antagonist 2-APB had no effect on Epac stimulated CICR in the Oestreich study. These issues remain to be addressed but could have something to do with differences in methodological approaches.

3.1.4. Scaffolding of PLC ϵ in the heart

From data discussed in the previous two sections, PLC ϵ seems to be involved in two independent processes in the cardiac myocyte. One concerns regulation of hypertrophy and hypertrophic gene expression through an as yet undefined mechanism and a second concerns regulation of cardiac contraction through PKC and CaMKII. This raises the question of whether these processes are directly connected or independent processes. To begin to address this question we began to examine the subcellular scaffolding of PLC ϵ in the heart [90].

Immunoprecipitation experiments from heart tissue indicate that PLC ϵ is in a complex with muscle specific A kinase anchoring protein (mAKAP) [90] where PLC ϵ is part of a multiprotein complex assembled on mAKAP with PKA, adenylyl cyclase, PDE4D3, Epac and other proteins [16,90]. Cotransfection and purified protein binding experiments indicate that the PLC ϵ directly interacts with mAKAP [90]. Thus the upstream activator Epac and the target PLC ϵ are scaffolded together in the same complex. Since mAKAP is highly localized to the perinuclear region of myocytes [55] this serves to scaffold PLC ϵ as well the other proteins of the macromolecular complex to the nuclear membrane [41,90]. Scaffolding of PLC ϵ at the nucleus suggested a role for mAKAP-bound, nuclear scaffolded PLC ϵ in regulation of hypertrophic gene expression and hypertrophy. To test for a role of PLC ϵ /mAKAP scaffolding, the protein interaction surfaces between PLC ϵ and mAKAP were mapped and small domains on either mAKAP or PLC ϵ that could be used to disrupt PLC ϵ /mAKAP binding were identified. Exogenous expression of these domains in NRVMs disrupted endogenous PLC ϵ -mAKAP complexes and suppressed ET-1-dependent hypertrophy [90]. Thus it appears that PLC ϵ scaffolded to mAKAP at the nucleus is important for regulation of the development of hypertrophy and heart failure. This scaffolding could also be important for the Epac-dependent regulation of nuclear Ca $^{2+}$ reported recently [57].

In addition to scaffolding to mAKAP, PLC ϵ is found in a complex with RyR2 in PLC ϵ immunoprecipitates from heart extracts. In contrast to mAKAP, scaffolding of PLC ϵ to RyR2 may be indirect since PLC ϵ only binds weakly to RyR2 in cotransfected HEK293 cells (Malik, in preparation). mAKAP has previously been reported to scaffold to RyR2 and could possibly scaffold PLC ϵ to RyR2 in the SR [50,60]. Arguing against this scaffolding mechanism for PLC ϵ binding to RyR2, however, is that the amount of RyR2 in mAKAP complexes isolated from heart is much lower than the amount of RyR2 isolated from PLC ϵ complexes. These data indicate that there is a significant pool of PLC ϵ associated with RyR2 that is not associated with mAKAP. In addition, coexpression of mAKAP with RyR2 and PLC ϵ does not enhance interactions of PLC ϵ with RyR2 suggesting that mAKAP binding to RyR2 does not mediate binding of PLC ϵ to RyR2. Thus the protein-protein interactions that drive PLC ϵ binding to RyR2 are undefined, but it is reasonable to speculate that this scaffolding interaction is important for regulation of RyR2 function in the sarcoplasmic reticulum. Since RyR2 has been shown to scaffold multiple proteins including CaMKII and PKC, the scaffolding of PLC ϵ to RyR2 would place many of the signaling partners in the correct place for regulation of RyR2 [50].

Overall, scaffolding of PLC ϵ to discrete locations in the cardiac myocyte appears to be critical for its ability to regulate distinct functions (see Fig. 3). Thus, scaffolding at RyR2 is likely to be involved in CICR, whereas scaffolding at mAKAP located on the nuclear envelope




Fig. 3. PLC ϵ scaffolding in cardiac myocytes. PLC ϵ is scaffolded at different subcellular locations to perform distinct functions. PLC ϵ scaffolded to RyR2 in the sarcoplasmic reticulum (SR) functions in CICR; PLC ϵ scaffolded to mAKAP at the nuclear (Nuc) envelope is involved in hypertrophy. Additional roles for PLC ϵ at the plasma membrane PM may also exist.

may regulate hypertrophic gene expression. Thus far, scaffolding interactions in native cells have only been examined for cardiomyocytes, but it is likely that in other cell types PLC ϵ can also scaffold, through different binding partners, to distinct locations in various differentiated cell types. Relative to other PLC isoforms, protein expression of PLC ϵ is quite low, so scaffolding to specific sites may be important to allow specific signals to generate IP $_3$ or DAG locally. In the case of SR Ca $^{2+}$ release, the critical PLC product appears to be DAG since PKC activation is required for the response [53], although, as discussed earlier, one study debates this notion [57]. At the nucleus it is possible that either IP $_3$ or DAG or both are needed locally to drive hypertrophy. In this regard PIP $_2$ is thought to be localized primarily to the plasma membrane, while phosphatidylinositol 4-P (PI4P) is more broadly distributed in ER and Golgi [4]. Both PIP $_2$ and PI4P are substrates for PLC ϵ in vitro [63]. Since the ER is continuous with the nuclear envelope, PI4P may be the available substrate for PLC ϵ at the nuclear envelope. This would suggest that the relevant product of PLC ϵ at the nuclear envelope would be DAG since IP $_3$ would not be produced from this reaction.

3.2. Role of PLC ϵ in pancreatic β cell function

Glucagon-like peptide-1 (GLP-1), is a gastrointestinal “incretin” hormone that stimulates pancreatic β cell cAMP production. It lowers levels of blood glucose by stimulating the release of insulin from islet β cells. Thus, analogs of GLP-1 are now in use as novel blood glucose-lowering agents for treatment of patients with type 2 diabetes mellitus (T2DM) to increase insulin release [45]. GLP-1 binds to its GPCR expressed on β cells [81] resulting in cAMP production and a PKA-mediated potentiation of depolarization-induced CICR from endoplasmic reticulum Ca $^{2+}$ stores. Based on these findings, it was proposed that under conditions in which Ca $^{2+}$ influx is initiated by glucose-dependent depolarization, PKA-mediated phosphorylation of intracellular Ca $^{2+}$ release channels results in a sensitization of these channels to the stimulatory action of Ca $^{2+}$ so that CICR is facilitated [18,32]. However, evidence for a PKA-independent action of GLP-1 to raise the [Ca $^{2+}$] $_i$ was found in a study of mouse β cells [6]. Subsequently, it was demonstrated that this action of GLP-1 was mediated by Epac2 [37]. Consistent with such findings, cpTOME was shown to promote CICR in human β cells [40].

Given the role of PLC ϵ in regulation of cAMP-dependent CICR in the heart, studies were then initiated to determine whether Epac-dependent activation of PLC ϵ might explain the PKA-independent action of GLP-1 to regulate CICR in β cells. In these studies, the GLP-1 receptor agonist Exendin-4 activated PKA and Epac2 while also facilitating CICR triggered by the uncaging of Ca $^{2+}$ [19]. The PKA-dependent action of Exendin-4 was antagonized by PKA inhibitor H-89, was mimicked by PKA activator 6-Bnz-cAMP-AM, and was still measurable in β cells of PLC ϵ KO and Epac2 KO mice. In contrast, the Epac2-mediated action of Exendin-4 was resistant to H-89, was mimicked by cpTOME, and was absent in β cells of PLC ϵ KO and Epac2 KO mice [19]. Furthermore, a

rescue of CICR could be achieved after transduction of PLC ϵ KO mouse β cells with wild-type PLC ϵ , but not a catalytically dead PLC ϵ [19]. The ability of cpTOME to facilitate CICR was abrogated in mouse β cells transduced with RapGAP, indicating that CICR was under the control of a signal transduction “module” comprised of Epac2, Rap, and PLC ϵ (Fig. 2A).

These findings are remarkable in view of the fact that Epac1, Rap, and PLC ϵ regulate CICR downstream of cAMP in mouse cardiomyocytes [53,54]. Just as remarkable is the finding that for both cell types, the ability of cpTOME to facilitate CICR was antagonized by inhibitors of PKC and CaMKII [19,53]. However, the intracellular Ca $^{2+}$ release channel that mediates Epac2/PLC ϵ -dependent CICR in β cells has not yet been clearly defined. As has been discussed, in mouse heart the Epac/PLC ϵ /CaMKII pathway modulates CICR through RyR2. In human β cells, CICR facilitated by GLP-1 resulted, at least in part, from the gating of RyR2 [32]. Furthermore, CICR stimulated by cpTOME was blocked by ryanodine [12,40]. However, in mouse β cells evidence exists that CICR is mediated not only by ryanodine receptors, but also by IP $_3$ receptors [18,38]. Thus, for human β cells and perhaps mouse β cells we envision three possible scenarios to explain available data (Fig. 2B): 1) PLC ϵ directly modulates RyR2 in a PKC and CaMKII-dependent manner, analogous to what occurs in the cardiac myocyte, 2) PLC ϵ indirectly modulates RyR2 by first activating IP $_3$ receptors, which then release Ca $^{2+}$ that serves as a stimulus for the gating of RyR2, or 3) some combination of both. Taken as a whole, such findings indicate the existence of an evolutionarily conserved mechanism of Ca $^{2+}$ mobilization in β cells and cardiomyocytes, one that utilizes Epac proteins and Rap GTPases to activate PLC ϵ , and results in activation of PKC and CaMKII and their sequestrae.

PLC ϵ is also important in the cAMP-dependent potentiation of glucose-stimulated insulin secretion (GSIS) from β cells [20]. GSIS from mouse β cells was potentiated by cpTOME, and this action of cpTOME was disrupted in β cells of PLC ϵ KO mice. The defect in insulin secretion measured in the islets of PLC ϵ KO mice was highly selective in that activators of PKA retained their abilities to potentiate GSIS. For β cells of wild-type mice, the insulin secretagogue action of cpTOME was associated with its ability to facilitate CICR, and was disrupted in β cells of PLC ϵ KO mice [19]. Since CICR in β cells is known to be positively coupled to Ca $^{2+}$ -dependent exocytosis of insulin [38,39], these data together indicate that Epac2-mediated activation of PLC ϵ regulates CICR in a PKA-independent manner to potentiate GSIS.

Based on these findings concerning β cells, we propose that the above-described signaling mechanism is of importance to the treatment of type 2 diabetes. β cells act as blood glucose sensors which match a rise of blood glucose concentration to an appropriate rate of β cell insulin secretion. Secreted insulin then acts at insulin-responsive tissues to stimulate glucose uptake, thereby lowering levels of blood glucose [64]. The ability of β cells to act as blood glucose sensors derives from the fact that an increase of blood glucose concentration leads to accelerated glucose metabolism within β cells. This glucose metabolism generates an increase of cytosolic ATP/ADP concentration ratio, and this metabolic signal is responsible for the closure of ATP-sensitive K $^+$ channels with concomitant β cell depolarization. Ensuing influx of Ca $^{2+}$ through voltage-dependent Ca $^{2+}$ channels produces an increase of [Ca $^{2+}$] $_i$ that initiates exocytosis of insulin stored within the secretory vesicles [28]. In T2DM the blood glucose concentration is chronically elevated due to the inability of β cells to secrete sufficient quantities of insulin. This pathology is due, at least in part, to the failure of β cell glucose metabolism to generate an increase of [Ca $^{2+}$] $_i$ that would normally initiate insulin exocytosis. One therapy for the treatment of T2DM involves the administration of agents that have the capacity to restore normal Ca $^{2+}$ handling in β cells. GLP-1 analogs might have the ability to facilitate CICR in β cells of T2DM patients, thereby restoring Ca $^{2+}$ handling and insulin exocytosis. In theory, strategies that target the Epac/PLC ϵ pathway, such as Epac or PLC ϵ activators, would also enhance CICR and rescue insulin exocytosis perhaps under conditions where β -cells have become refractory to GLP-1 stimulation.

3.3. PLC ϵ in inflammation and cancer

The observation that PLC ϵ is a direct effector of the proto-oncogene Ras raised considerable excitement about the potential role of PLC ϵ in cancer. Ras activates multiple effector pathways and in many cancers an important target of mutationally activated Ras in many cancers is the Raf/ERK pathway that drives cell division and transformation. To investigate the role of PLC ϵ in Ras-dependent transformation PLC $\epsilon^{\Delta x/\Delta x}$ and PLC $\epsilon^{+/+}$ mice were exposed to a two-stage chemical carcinogenesis protocol. The first-stage of this treatment protocol utilizes 7,12-dimethylbenz(a)anthracene (DMBA) to induce Ras mutations; 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment in a follow-up second stage facilitates clonal expansion of cells containing Ras mutations [3]. In this model Bai et al. demonstrated that both the number of squamous cell tumors and the size of the tumors were reduced in PLC $\epsilon^{\Delta x/\Delta x}$ animals. In the absence of an initiating DMBA stimulus, TPA also induced epidermal proliferation which was significantly reduced in PLC $\epsilon^{\Delta x/\Delta x}$ animals.

To understand the mechanisms for PLC ϵ dependent regulation of tumor initiation and growth, epidermal keratinocytes and dermal fibroblasts were isolated from PLC $\epsilon^{\Delta x/\Delta x}$ and PLC $\epsilon^{+/+}$ mice and tested for alteration in cell growth in response to growth factors in an organotypic cell culture system [35]. PLC ϵ is expressed both in the fibroblasts and in keratinocytes but is much more abundant in the fibroblasts. This suggested a possible direct role for PLC ϵ in the proliferation of these cells, but in contrast to the intact animal, no differences in growth were observed in the fibroblasts nor in the keratinocytes isolated from the wt vs. KO PLC ϵ genotypes nor were differences in proliferative signals observed in response to TPA. This led to the hypothesis that PLC ϵ was influencing dermal proliferation indirectly. It was noted that there was a reduction in skin inflammation in the skin of PLC $\epsilon^{\Delta x/\Delta x}$ mice exposed TPA treatment, suggesting that PLC ϵ might indirectly promote tumor formation by locally regulating inflammation. In fact, it was shown that fibroblasts isolated from PLC $\epsilon^{\Delta x/\Delta x}$ mice had reduced production of several proinflammatory cytokines. In addition, fewer inflammatory leukocytes were recruited to the skin in response to TPA in the PLC $\epsilon^{\Delta x/\Delta x}$ mice. These findings support the hypothesis that PLC ϵ can regulate inflammatory responses, and led to the proposal that it was the proinflammatory actions of PLC ϵ in fibroblasts that contribute to tumor growth in this model.

To test the notion that the role of PLC ϵ in tumor cell proliferation in general might be due to regulation of the local extracellular environment, the Katoaka group examined another cancer model in which inflammation has been shown to play a major role. Apc^{Min/+} mice lacking one copy of the adenomatous polyposis coli (Apc) gene are a well established model for intestinal tumorigenesis where inflammatory processes play an important role in tumorigenesis and cancer progression. Spontaneous intestinal tumor formation was significantly suppressed in Apc^{Min/+} mice bred into a PLC $\epsilon^{\Delta x/\Delta x}$ background [1,46]. Additionally the conversion of low grade tumors into high grade adenocarcinomas was dramatically reduced by loss of PLC ϵ activity. That two different stages of tumor development were influenced by PLC ϵ suggested PLC ϵ involvement in two distinct mechanisms. The development of low grade tumors is strongly dependent on angiogenesis, and VEGF production was shown to be significantly reduced in tumors isolated from PLC $\epsilon^{\Delta x/\Delta x}$ animals. The second stage is thought to be strongly dependent on inflammation, and COX2 expression was significantly reduced in PLC $\epsilon^{\Delta x/\Delta x}$ mice. Thus, for this model of intestinal tumorigenesis, PLC ϵ regulates the expression of factors that regulate different stages of tumor progression and does so via distinct mechanisms, one involving angiogenesis and a second involving the production of inflammatory mediators. That both skin and intestinal cancer can be regulated in an inflammatory mediator-dependent manner through PLC ϵ supports the idea that PLC ϵ may regulate cancer progression for tumors that are modulated by inflammatory status. Recently, genome wide association (GWAS) studies have implicated PLC ϵ in esophageal

squamous cell carcinoma and gastric adenocarcinoma [1,86], conditions that may also depend on chronic inflammation, although whether the PLC ϵ polymorphisms identified in this study may influence PLC ϵ activity is unresolved.

The data described above suggest that PLC ϵ may play a general role as a proinflammatory mediator in multiple tissues through actions that do not directly involve effects of PLC ϵ actions in inflammatory leukocytes. Follow up analyses have implicated PLC ϵ in allergic contact hypersensitivity, and over expression of PLC ϵ in the skin tissue of mice causes spontaneous skin inflammation [33]. Thus, the major role for PLC ϵ in inflammation appears to be in regulating the production of proinflammatory mediators. The molecular mechanism(s) underlying the regulation of the production of proinflammatory mediators by PLC ϵ remains uncertain. In the case of TPA-dependent skin hyperplasia, one proposed mechanism is through the regulation of two DAG dependent targets, Ras-GRP3 and PKC. RasGRP3 is a Rap1 GEF that is directly activated by DAG and TPA, and it is also dependent on PKC phosphorylation for activation [35]. Thus, TPA could stimulate PLC ϵ activity in dermal fibroblasts through the production of activated Rap1 that can directly bind and regulate PLC ϵ . Downstream of PLC ϵ , one recent study in cell culture suggests that PLC ϵ may cooperate with NF κ B to modulate expression of certain cytokines [25]. Additionally, our recent work using astrocytes as a model of inflammatory cells in the brain demonstrates that GPCR agonists such as thrombin, LPA and SIP require PLC ϵ to regulate NF κ B and cyclooxygenase expression (Dusaban, in preparation).

PLC epsilon is not the only PLC isoform that has been linked to inflammation. In immune cells, PLC γ_2 signals downstream of various tyrosine kinase-linked receptors to initiate pro-inflammatory responses [23,84]. PLC δ isoforms are involved in the innate immune response downstream of chemotactic peptide signaling, which is involved in the signaling cascades within leukocytes that direct immune cell migration and secretion of inflammatory factors [89]. PLC δ on the other hand, suppresses production of inflammatory cytokine production in keratinocytes, thereby suppressing activation and recruitment of immune cells [34]. These different enzymes elicit diverse reactions likely due, in part, to their expression in different cell types. In cells such as keratinocytes, both PLC ϵ and PLC δ are expressed and they appear to perform opposing functions. The ability of Ras subfamily small G-proteins to regulate PLC ϵ is unique, however, as is the aforementioned spatial and temporal activation of this PLC isoform, thus it is likely that PLC ϵ serves to regulate the expression of inflammatory genes in ways that other PLC isoforms do not.

4. Roles for PLC ϵ in human disease

4.1. PLC ϵ in the kidney

In a recent search for genes involved in childhood nephrotic syndrome, PLC ϵ mutations were identified as autosomal recessive determinants of this disease [31]. These mutations included missense mutations that resulted in truncation of the PLC ϵ protein, or in single site polymorphisms. The disease course correlated with the severity of the PLC ϵ mutation. Patients with homozygous truncation mutations had an earlier onset of proteinuria and earlier development of end-stage kidney disease than did patients with single amino acid substitutions in the gene.

PLC ϵ is highly expressed in glomerular podocytes [31]. Podocytes are epithelial cells with foot-like processes that form connections through various adhesion proteins which form a key part of the glomerular filtration barrier. This barrier functions in the glomerulus to allow the relatively free flow of liquid and aqueous solutes while retaining plasma proteins such as albumin to maintain blood protein levels. Various genetically inherited nephropathies result from inherited mutations in the proteins that form or maintain this filtration barrier, resulting in disruption of podocyte connections and leakage of proteins into the urine (proteinuria) [48]. The signaling role of PLC ϵ in

podocytes in the normal physiology of podocytes and in glomerular kidney disease is not understood. An intriguing possibility is that PLC ϵ is involved in the regulation of a DAG sensitive Trp channel (TrpC6). TrpC6 plays an important role in regulating Ca²⁺ signaling in the podocyte, and mutations in TrpC6 are associated with glomerular kidney disease [15]. A connection between PLC ϵ activity and TrpC6 function has not yet been supported by direct data. Some protein–protein interactions between PLC ϵ and podocyte proteins such as IQGAP and B-Raf have been reported [11], but whether these interactions are involved in the ability of PLC ϵ to regulate podocyte development or function remains unresolved.

Patients with PLC ϵ mutations have impaired glomerular development, thus it has been suggested that PLC ϵ signaling may be involved in glomerular development [31]. However, PLC ϵ deletion in mice does not lead to increased proteinuria nor does it appear to affect glomerular development, a finding that seemingly rules out a direct role of PLC ϵ signaling in podocyte or glomerular development (unpublished observations). On the other hand, PLC ϵ deletion in zebrafish leads to a defect in glomerular filtration function and development of a disorganized filtration barrier characteristic of kidney disease [31]. It is likely that genetic background or environmental factors influence the ability of PLC ϵ dysfunction to produce a glomerular phenotype.

4.2. PLC ϵ in esophageal cancer and gastric adenocarcinoma

Recent studies using genomic based approaches have identified an association of the PLC ϵ gene with various human cancers. Two separate genome-wide association (GWAS) studies identified PLCE1 single nucleotide polymorphisms (SNPs) associated with esophageal squamous cell carcinoma (ESCC) [1,86]. These studies analyzed DNA SNPs from over 1000 patients with ESCC and compared them with DNA isolated from control individuals. Both studies identified polymorphisms in either the coding or non coding regions of the PLCE1 gene, and demonstrated that these polymorphisms were associated with ESCC. One of these studies found that the same PLCE1 SNPs associated with ESCC were also associated with gastric adenocarcinoma [1]. Two polymorphisms resulted in single amino acid substitutions in the PLC ϵ coding sequence, while three other SNPs were silent in terms of the protein sequence. One substitution independently identified by both groups was R1927H which is located in the C2 domain, and the other was I177T which is in the Y domain portion of the catalytic domain (see Fig. 1). Whether these or the other non-coding alterations associated with the PLCE1 SNPs alter PLCE1 function or expression is unknown. Accordingly, while these SNPs are associated with the disease, it is unclear whether alterations in PLC ϵ function or expression are causal or merely correlated with the ESCC or gastric adenocarcinoma.

5. Conclusion and outlook

One of the surprising results of these summarized studies is the dramatic impact of PLC ϵ on cellular physiology despite the fact that it is a relatively low abundance protein expressed in the context of multiple other more abundant PLC isoforms in the same cell. This underscores an overall recognition that the functional importance of a protein in cellular physiology does not necessarily correlate with abundance. Of additional interest is the fact that PLC ϵ activation occurs in response to the activation of GPCRs that have been traditionally thought to be coupled to inositol phosphate production via Gq and PLC β . This is manifest in the role of PLC ϵ in more sustained signals emanating from multiple receptors. Another critical point is the apparent localization of PLC ϵ to internal membrane structures, such as ER, Golgi and perinuclear membranes that are not thought to be rich in PIP₂, but rather are enriched in PI4P; As discussed above, hydrolysis of PI4P will generate DAG but not IP₃ again suggesting a role in sustained processes perhaps involving DAG rather than IP₃. Signals involving DAG formation and activation of downstream kinases such

as PKC and PKD may be sustained and compartmentalized in this way. A final theme that emerges from these studies is that intracellular scaffolding can specify cellular function. This is not a new concept overall, but the demonstration that PLC scaffolding has a significant impact on physiological functions is novel.

Several of the physiological functions discussed above indicate that PLC ϵ may be a therapeutic target. In hypertrophy PLC ϵ appears to be a central player that integrates signals from multiple stimuli. In this case inhibition of PLC ϵ function could be a strategy for treatment of heart failure. Similarly, inhibition of PLC ϵ could prevent inflammatory reactions associated with tumor development in some cancers or in other diseases in which inflammation plays a major role. Disrupting PLC ϵ scaffolding in the cardiac myocyte inhibits development of hypertrophy and could also be a useful strategy to inhibit development of heart failure in particular since the mA-KAP scaffolding is likely to be unique to myocytes. In pancreatic β -cells increasing, rather than interfering with PLC ϵ function has the potential to increase insulin secretion in response to natural changes in the levels of incretin hormones such as GLP1 and thus could be an approach to treatment of Type 2 diabetes.

It is likely that PLC ϵ plays important roles in other physiologies that have yet to be investigated. PLC ϵ is highly enriched in the lung suggesting that PLC signaling plays a role in asthma through mediating contraction of bronchial smooth muscle. PLC ϵ signaling may be associated with Epac in many cell types and could be a general regulator of CICR in response to cyclic AMP in multiple excitable cells. Answering these questions will require more detailed phenotype analysis of PLC ϵ ^{-/-} mice. Thus, while the general basis for receptor stimulated phosphoinositide hydrolysis is well established some unexpected roles for PLC isoform specific phosphoinositide signaling networks in specific physiological functions continue to emerge. Studies with PLC ϵ knockout animals have been invaluable in revealing specific phenotypes and coupled with detailed tissue, cell and biochemical analysis, novel detailed physiological signaling mechanisms will be revealed.

Acknowledgments

This work was supported by National Institutes of Health grants GM R01 053536 to A. V. S., GM R01 036927 to J.H.B., and DK R01 045817 and DK R01 069575 to G.G.H.

References

- [1] C.C. Abnet, N.D. Freedman, N. Hu, Z. Wang, K. Yu, X.-O. Shu, J.-M. Yuan, W. Zheng, S.M. Dawsey, L.M. Dong, et al., *Nature Genetics* 42 (2010) 764–767.
- [2] J.W. Adams, Y. Sakata, M.G. Davis, V.P. Sah, Y. Wang, S.B. Liggett, K.R. Chien, J.H. Brown, G.W. Dorn II, *Proceedings of the National Academy of Sciences of the United States of America* 95 (1998) 10140–10145.
- [3] Y. Bai, H. Edamatsu, S. Maeda, H. Saito, N. Suzuki, T. Satoh, T. Kataoka, *Cancer Research* 64 (2004) 8808–8810.
- [4] T. Balla, Z. Szentpetery, Y.J. Kim, *Physiology* 24 (2009) 231–244.
- [5] D.M. Bers, *Annual Review of Physiology* 70 (2008) 23–49.
- [6] H.P. Bode, B. Moormann, R. Dabew, B. Göke, *Endocrinology* 140 (1999) 3919–3927.
- [7] T.D. Bunney, R. Harris, N.L.O. Gandarillas, M.B. Josephs, S.M. Roe, S.C. Sorli, H.F. Paterson, F. Rodrigues-Lima, D. Esposito, C.P. Ponting, et al., *Molecular Cell* 21 (2006) 495–507.
- [8] M. Camps, A. Carozzi, P. Schnabel, A. Scheer, P.J. Parker, P. Gierschik, *Nature* 360 (1992) 684–686.
- [9] G. Carpenter, T. Hernandez-Sotomayor, G. Jones, *Advances in Second Messenger and Phosphoprotein Research* 28 (1993) 179–185.
- [10] O. Cazorla, A. Lucas, F. Poirier, A. Lacampagne, F. Lezoualc'h, *Proceedings of the National Academy of Sciences of the United States of America* 106 (2009) 14144–14149.
- [11] H. Chaib, B.E. Hoskins, S. Ashraf, M. Goyal, R.C. Wiggins, F. Hildebrandt, *American Journal of Physiology. Renal Physiology* 294 (2008) F93–F99.
- [12] O.G. Chepurny, G.G. Kelley, I. Dzshura, C.A. Leech, M.W. Roe, E. Dzshura, X. Li, F. Schwede, H.G. Genieser, G.G. Holz, *American Journal of Physiology, Endocrinology and Metabolism* 298 (2010) E622–E633.
- [13] S. Citro, S. Malik, E.A. Oestreich, J. Radeff-Huang, G.G. Kelley, A.V. Smrcka, J.H. Brown, *Proceedings of the National Academy of Sciences of the United States of America* 104 (2007) 15543–15548.
- [14] D.D. D'Angelo, Y. Sakata, J.N. Lorenz, G.P. Boivin, R.A. Walsh, S.B. Liggett, G.W. Dorn II, *Proceedings of the National Academy of Sciences of the United States of America* 94 (1997) 8121–8126.

- [15] A. Dietrich, V. Chubanov, T. Gudermann, *Journal of the American Society of Nephrology* 21 (2010) 736–744.
- [16] K.L. Dodge-Kafka, J. Soughayer, G.C. Pare, J.J. Carlisle Michel, L.K. Langeberg, M.S. Kapiloff, J.D. Scott, *Nature* 437 (2005) 574–578.
- [17] G.W. Dorn II, J.H. Brown, *Trends in Cardiovascular Medicine* 9 (1999) 26–34.
- [18] O. Dyachok, E. Gylfe, *Journal of Biological Chemistry* 279 (2004) 45455–45461.
- [19] I. Dzhura, O.G. Chepurny, G.G. Kelley, C.A. Leech, M.W. Roe, E. Dzhura, P. Afshari, S. Malik, M.J. Rindler, X. Xu, et al., *Journal de Physiologie* 588 (2010) 4871–4889.
- [20] I. Dzhura, O.G. Chepurny, C.A. Leech, M.W. Roe, E. Dzhura, X. Xu, Y. Lu, F. Schwede, H.-G. Genieser, A.V. Smrcka, et al., *Islets* 3 (2011) 121–128.
- [21] L.O. Essen, O. Perisic, R. Cheung, M. Katan, R.L. Williams, *Nature* 380 (1996) 595–602.
- [22] T.M. Filtz, D.R. Grubb, T.J. McLeod-Dryden, J. Luo, E.A. Woodcock, *The FASEB Journal* 23 (2009) 3564–3570.
- [23] D.B. Graham, C.M. Robertson, J. Bautista, F. Mascarenhas, M.J. Diacovo, V. Montgrain, S.K. Lam, V. Cremasco, W.M. Dunne, R. Faccio, et al., *The Journal of Clinical Investigation* 117 (2007) 3445–3452.
- [24] M.D. Hains, M.R. Wing, S. Maddileti, D.P. Siderovski, T.K. Harden, *Molecular Pharmacology* 69 (2006) 2068–2075.
- [25] Y. Harada, H. Edamatsu, T. Kataoka, *Biochemical and Biophysical Research Communications* 414 (2011) 106–111.
- [26] T.K. Harden, J. Sondek, *Annual Review of Pharmacology and Toxicology* 46 (2006) 355–379.
- [27] T.K. Harden, G.L. Waldo, S.N. Hicks, J. Sondek, *Chemistry Review* 111 (2011) 6120–6129.
- [28] J.C. Henquin, *Diabetes* 49 (2000) 1751–1760.
- [29] S.N. Hicks, M.R. Jezky, S. Gershburg, J.P. Seifert, T.K. Harden, J. Sondek, *Molecular Cell* 31 (2008).
- [30] D.W. Hilgemann, R. Ball, *Science* 273 (1996) 956–959.
- [31] B. Hinkes, R.C. Wiggins, R. Gbadejesin, C.N. Vlangos, D. Seelow, G. Nurnberg, P. Garg, R. Verma, H. Chaib, B.E. Hoskins, et al., *Nature Genetics* 38 (2006) 1397–1405.
- [32] G.G. Holz, C.A. Leech, R.S. Heller, M. Castonguay, J. Habener, *Journal of Biological Chemistry* 274 (1999) 14147–14156.
- [33] L. Hu, H. Edamatsu, N. Takenaka, S. Ikuta, T. Kataoka, *Journal of Immunology* 184 (2010) 993–1002.
- [34] M. Ichinohe, Y. Nakamura, K. Sai, M. Nakahara, H. Yamaguchi, K. Fukami, *Biochemical and Biophysical Research Communications* 356 (2007) 912–918.
- [35] S. Ikuta, H. Edamatsu, M. Li, L. Hu, T. Kataoka, *Cancer Research* 68 (2008) 64–72.
- [36] T.G. Jin, T. Satoh, Y. Liao, C. Song, X. Gao, K. Kariya, C.D. Hu, T. Kataoka, *Journal of Biological Chemistry* 276 (2001) 30301–30307.
- [37] G. Kang, O.G. Chepurny, G.G. Holz, *Journal de Physiologie* 536 (2001) 375–385.
- [38] G. Kang, O.G. Chepurny, M.J. Rindler, L. Collis, Z. Chepurny, W.H. Li, M. Harbeck, M.W. Roe, G.G. Holz, *Journal de Physiologie* 566 (2005) 173–188.
- [39] G. Kang, G.G. Holz, *Journal de Physiologie* 546 (2003) 175–189.
- [40] G. Kang, J.W. Joseph, O.G. Chepurny, M. Monaco, M.B. Wheeler, J.L. Bos, F. Schwede, H.G. Genieser, G.G. Holz, *Journal of Biological Chemistry* 278 (2003) 8279–8285.
- [41] M.S. Kapiloff, N. Jackson, N. Airhart, *Journal of Cell Science* 114 (2001) 3167–3176.
- [42] G.G. Kelley, K.A. Kaproth-Joslin, S.E. Reks, A.V. Smrcka, R.J.H. Wojcikiewicz, *Journal of Biological Chemistry* 281 (2006) 2639–2648.
- [43] G.G. Kelley, S.E. Reks, J.M. Ondrako, A.V. Smrcka, *EMBO Journal* 20 (2001) 743–754.
- [44] G.G. Kelley, S.E. Reks, A.V. Smrcka, *Biochemical Journal* 378 (2004) 129–139.
- [45] C.A. Leech, I. Dzhura, O.G. Chepurny, G. Kang, F. Schwede, H.G. Genieser, G.G. Holz, *Progress in Biophysics and Molecular Biology* 107 (2011) 236–247.
- [46] M. Li, H. Edamatsu, R. Kitazawa, S. Kitazawa, T. Kataoka, *Carcinogenesis* 30 (2009) 1424–1432.
- [47] I. Lopez, E.C. Mak, J. Ding, H.E. Hamm, J.W. Lomasney, *Journal of Biological Chemistry* 276 (2001) 2758–2765.
- [48] M. Löwik, P. Groenen, E. Levtschenko, L. Monnens, L. van den Heuvel, *European Journal of Pediatrics* 168 (2009) 1291–1304.
- [49] A.M. Lyon, V.M. Tesmer, V.D. Dhamsania, D.M. Thal, J. Gutierrez, S. Chowdhury, K.C. Suddala, J.K. Northup, J.J.G. Tesmer, *Nature Structural and Molecular Biology* 18 (2011) 999–1005.
- [50] S.O. Marx, S. Reiken, Y. Hisamatsu, T. Jayaraman, D. Burkhoff, N. Rosembli, A.R. Marks, *Cell* 101 (2000) 365–376.
- [51] J. Meisenhelder, P.G. Suh, S.G. Rhee, T. Hunter, *Cell* 57 (1989) 1109–1122.
- [52] M. Nakahara, M. Shimozawa, Y. Nakamura, Y. Irino, M. Morita, Y. Kudo, K. Fukami, *Journal of Biological Chemistry* 280 (2005) 29128–29134.
- [53] E.A. Oestreich, S. Malik, S.A. Goonasekera, B.C. Blaxall, G.G. Kelley, R.T. Dirksen, A.V. Smrcka, *Journal of Biological Chemistry* 284 (2009) 1514–1522.
- [54] E.A. Oestreich, H. Wang, S. Malik, K.A. Kaproth-Joslin, B.C. Blaxall, G.G. Kelley, R.T. Dirksen, A.V. Smrcka, *Journal of Biological Chemistry* 282 (2007) 5488–5495.
- [55] G.C. Pare, J.L. Easlick, J.M. Mislow, E.M. McNally, M.S. Kapiloff, *Experimental Cell Research* 303 (2005) 388–399.
- [56] L. Pereira, M. Metrich, M. Fernandez-Velasco, A. Lucas, J. Leroy, R. Perrier, E. Morel, R. Fischmeister, S. Richard, J.P. Benitah, et al., *Journal de Physiologie* 583 (2007) 685–694.
- [57] L. Pereira, G. Ruiz-Hurtado, E. Morel, A.-C. Laurent, M. Métrich, A. Dominguez-Rodríguez, S. Lauton-Santos, A. Lucas, J.-P. Benitah, D.M. Bers, et al., *Journal of Molecular and Cellular Cardiology* 52 (2012) 283–291.
- [58] M.J. Rebecchi, S.N. Pentylala, *Physiological Reviews* 80 (2000) 1291–1335.
- [59] S.G. Rhee, *Annual Review of Biochemistry* 70 (2001) 281–312.
- [60] M.L. Ruehr, M.A. Russell, D.G. Ferguson, M. Bhat, J. Ma, D.S. Damron, J.D. Scott, M. Bond, *Journal of Biological Chemistry* 278 (2003) 24831–24836.
- [61] M. Schmidt, S. Evellin, P. Weernink, F. von Dorp, H. Rehmann, J. Lomasney, K. Jakobs, *Nature Cell Biology* 3 (2001) 1020–1024.
- [62] J.A. Schroeder, L.F. Jackson, D.C. Lee, T.D. Camenisch, *Journal of Molecular Medicine* 81 (2003) 392–403.
- [63] J.P. Seifert, M.R. Wing, J.T. Snyder, S. Gershburg, J. Sondek, T.K. Harden, *Journal of Biological Chemistry* 279 (2004) 47992–47997.
- [64] S. Seino, T. Shibasaki, K. Minami, *The Journal of Clinical Investigation* 121 (2011) 2118–2125.
- [65] M. Shibatohe, K. Kariya, Y. Liao, C.D. Hu, Y. Watari, M. Goshima, F. Shima, T. Kataoka, *Journal of Biological Chemistry* 273 (1998) 6218–6222.
- [66] P. Simpson, *Circulation Research* 56 (1985) 884–894.
- [67] P. Simpson, A. McGrath, S. Savion, *Circulation Research* 51 (1982) 787–801.
- [68] P. Simpson, S. Savion, *Circulation Research* 50 (1982) 101–116.
- [69] A.V. Smrcka, J.R. Hepler, K.O. Brown, P.C. Sternweis, *Science* 251 (1991) 804–807.
- [70] A.V. Smrcka, P.C. Sternweis, *Journal of Biological Chemistry* 268 (1993) 9667–9674.
- [71] C. Song, C.D. Hu, M. Masago, K. Kariya, Y. Yamawaki-Kataoka, M. Shibatohe, D. Wu, T. Satoh, T. Kataoka, *Journal of Biological Chemistry* 276 (2001) 2752–2757.
- [72] C. Song, T. Satoh, H. Edamatsu, D. Wu, M. Tadano, X. Gao, T. Kataoka, *Oncogene* 21 (2002) 8105–8113.
- [73] S.C. Sorli, T.D. Bunney, P.H. Sugden, H.F. Paterson, M. Katan, *Oncogene* 64 (2004) 90–100.
- [74] B.-C. Suh, B. Hille, *Annual Review of Biophysics* 37 (2008) 175–195.
- [75] P.G. Suh, J.I. Park, L. Manzoli, L. Cocco, J.C. Peak, M. Katan, K. Fukami, T. Kataoka, S. Yun, S.H. Ryu, *BMB Reports* 41 (2008) 415–434.
- [76] J.L. Sui, J. Petit-Jacques, D.E. Logothetis, *Proceedings of the National Academy of Sciences of the United States of America* 95 (1998) 1307–1312.
- [77] K. Swann, M.G. Larman, C.M. Saunders, F.A. Lai, *Reproduction* 127 (2004) 431–439.
- [78] M. Tadano, H. Edamatsu, S. Minamisawa, U. Yokoyama, Y. Ishikawa, N. Suzuki, H. Saito, D. Wu, M. Masago-Toda, Y. Yamawaki-Kataoka, et al., *Molecular and Cellular Biology* 25 (2005) 2191–2199.
- [79] S.J. Taylor, H.Z. Chae, S.G. Rhee, J.H. Exton, *Nature* 350 (1991) 516–518.
- [80] J.L. Thompson, T.J. Shuttleworth, *Journal de Physiologie* 589 (2011) 5057–5069.
- [81] B. Thorens, *Proceedings of the National Academy of Sciences of the United States of America* 89 (1992) 8641–8645.
- [82] G.L. Waldo, J.L. Boyer, A.J. Morris, T.K. Harden, *Journal of Biological Chemistry* 266 (1991) 14217–14225.
- [83] G.L. Waldo, T.K. Ricks, S.N. Hicks, M.L. Cheever, T. Kawano, K. Tsuboi, X. Wang, C. Montell, T. Kozasa, J. Sondek, et al., *Science* 330 (2010) 974–980.
- [84] D. Wang, J. Feng, R. Wen, J.-C. Marine, M.Y. Sangster, E. Parganas, A. Hoffmeyer, C.W. Jackson, J.L. Cleveland, P.J. Murray, et al., *Immunity* 13 (2000) 25–35.
- [85] H. Wang, E.A. Oestreich, N. Maekawa, T.A. Bullard, K.L. Vikstrom, R.T. Dirksen, G.G. Kelley, B.C. Blaxall, A.V. Smrcka, *Circulation Research* 97 (2005) 1305–1313.
- [86] L.-D. Wang, F.-Y. Zhou, X.-M. Li, L.-D. Sun, X. Song, Y. Jin, J.-M. Li, G.-Q. Kong, H. Qi, J. Cui, et al., *Nature Genetics* 42 (2010) 759–763.
- [87] N. Wetttschreck, H. Rutten, A. Zywiets, D. Gehring, T.M. Wilkie, J. Chen, K.R. Chien, S. Offermanns, *Nature Medicine* 7 (2001) 1236–1240.
- [88] M.R. Wing, D. Houston, G.G. Kelley, C.J. Der, D.P. Siderovski, T.K. Harden, *Journal of Biological Chemistry* 276 (2001) 48257–48261.
- [89] D. Wu, C.K. Huang, H. Jiang, *Journal of Cell Science* 113 (2000) 2935–2940.
- [90] L. Zhang, S. Malik, G.G. Kelley, M.S. Kapiloff, A.V. Smrcka, *Journal of Biological Chemistry* 286 (2011) 23012–23021.
- [91] Y. Zhou, M.R. Wing, J. Sondek, T.K. Harden, *Biochemical Journal* 391 (2005) 667–676.